Nexalin Technology To Present Clinical Data Showing 77.8% Anxiety Response Rate, Durable 8-Week Benefits, And No Serious Adverse Events From Its 15 mA, 77.5 Hz DIFS Deep-Brain Stimulation Platform, At 2026 NYC Neuromodulation Conference

Loading news article.

Nexalin Technology To Present Clinical Data Showing 77.8% Anxiety Response Rate, Durable 8-Week Benefits, And No Serious Adverse Events From Its 15 mA, 77.5 Hz DIFS Deep-Brain Stimulation Platform, At 2026 NYC Neuromodulation Conference | WAPE

Nexalin Technology To Present Clinical Data Showing 77.8% Anxiety Response Rate, Durable 8-Week Benefits, And No Serious Adverse Events From Its 15 mA, 77.5 Hz DIFS Deep-Brain Stimulation Platform, At 2026 NYC Neuromodulation Conference

Article summary

Related companies

Comments —